⁃ Age 55 years of age to 85 years old at the moment of inclusion

• Participant must understand and sign the protocol's informed consent document

• Participant must have central or non-central geographic atrophy (GA) in at least one eye. GA should be at least 0.75 disk areas (DA) in size but no more than 8 disk areas (DA); approximately 2.54 mm2 is 1 DA. (GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the retinal pigment epithelium (RPE), typically with exposure of underlying choroïdal blood vessels. Even if much of the RPE appears to be preserved and large choroïdal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA. If a patient has 2 eligible eyes; one eye will be the study eye, graded and evaluated during the whole duration of the study)

• Participant must have a steady fixation in the study eye in the foveal or parafoveal area and media clear enough for good quality photographs

• Participant must have visual acuity between 20/20 and 20/200 in the affected eye

• No suggestive sign of progressive multifocal leukoencephalopathy on brain MR Imaging within 3 months of Tecfidera© treatment Initiation (Only the patients randomized in the TECFIDERA Group will have to go through the MR Imaging)

• Male participants with female partners capable of conceiving children will be required to use contraception (condom) during the study and for four months after their last experimental treatment caps

• No documented history of heart disease, absence of family history of sudden death, and QTc duration within normal value (\<480ms)

• Participants must be affiliated to a social security scheme